Revision Skincare Announces 2 Studies Evaluating 30% THD Ascorbate Serum for Skin Quality Outcomes

Two peer-reviewed studies published in the Journal of Cosmetic Dermatology evaluated the cosmetic efficacy and tolerability of a high-strength vitamin C formulation containing 30% tetrahexyldecyl ascorbate (THD ascorbate) (C+ Correcting Complex 30%; Revision Skincare), Revision Skincare^® announced Thursday. The investigations included preclinical, ex vivo, and randomized, double-blind clinical assessments to examine the formulation’s effects on photodamaged and hyperpigmented skin.

The studies assessed multiple markers of skin quality, including tone uniformity, radiance, texture, and overall appearance, using investigator grading, subject self-assessment, and imaging modalities such as VISIA-CR, Primos 3D, and Antera 3D. Across evaluations, investigators reported visible improvements in skin brightness, tone evenness, and surface texture, as well as reductions in the appearance of photodamage and uneven pigmentation. The formulation was also reported to be well tolerated during regular use, with no adverse events noted in the summarized findings.

Preclinical data demonstrated antioxidant activity against high-energy visible (blue) light–induced oxidative stress, with reductions in reactive oxygen species and inhibition of melanogenesis. Additional ex vivo findings suggested improvements in skin architecture, including the epidermis, dermal-epidermal junction, and dermis.

THD ascorbate, a lipid-soluble vitamin C derivative, is designed to improve stability and skin compatibility relative to L-ascorbic acid. The authors noted that formulation challenges associated with traditional ascorbic acid, including oxidative instability and irritation potential, may be mitigated with THD ascorbate–based formulations. However, direct comparative efficacy versus L-ascorbic acid was not fully detailed in the summarized data.

"At Revision Skincare, clinical validation is foundational to how we prove our products' efficacy," said Dr. Alisar Zahr, vice president of research and clinical development at Revision Skincare®. "The publication of these peer‑reviewed studies underscores our commitment to rigorous science and highlights the role of THD ascorbate within C+ Correcting Complex 30%® as part of our evidence‑based approach to skincare innovation."